Similarly, the pan-HDAC inhibitor vorinostat (SAHA) [52], which is currently being used against Rhabdoid tumors in clinical trials, would be expected to robustly induce BRM expression; however, since this compound also inhibits HDAC2, it would also result in BRM acetylation and inactivation. This evidence concerns the gene HDAC2 and rhabdoid tumor.